← Back to Search

Unknown

AT-100 for COVID-19

Phase 1
Waitlist Available
Research Sponsored by Airway Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of initial at-100 dosing until the end of the dosing period, up to 7 days
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's safe for people with severe respiratory problems due to COVID-19 or pneumonia.

Eligible Conditions
  • COVID-19
  • Coronavirus
  • Not Applicable

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of initial at-100 dosing until the end of the dosing period, up to 7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of initial at-100 dosing until the end of the dosing period, up to 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determining the highest-tolerated & safety-tested AT-100 dose
Secondary outcome measures
Mechanical ventilation
Other outcome measures
Mortality

Trial Design

3Treatment groups
Experimental Treatment
Group I: AT-100 75 mg or 150 mg (Optional Cohort)Experimental Treatment1 Intervention
Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe & tolerated dose as determined by the prior 2 dosing levels.
Group II: AT-100 75 mgExperimental Treatment1 Intervention
Once daily AT-100 via intratracheal administration for up to 7 doses.
Group III: AT-100 150 mgExperimental Treatment1 Intervention
Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe & tolerated.

Find a Location

Who is running the clinical trial?

Airway Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
36 Total Patients Enrolled
Marc O. Salzberg, MDStudy ChairAirway Therapeutics, Inc.
1 Previous Clinical Trials
36 Total Patients Enrolled
Michael DePietro, MDStudy DirectorAirway Therapeutics, Inc.
1 Previous Clinical Trials
36 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The Lancet RheumatologyJournal
Covid-19-associated Hyperinflammation and Escalation of Patient Care: A Retrospective Longitudinal Cohort Study
Manson, Jessica J, Colin Crooks, Meena Naja, Amanda Ledlie, Bethan Goulden, Trevor Liddle, Emon Khan, et al.. 2020. “Covid-19-associated Hyperinflammation and Escalation of Patient Care: A Retrospective Longitudinal Cohort Study”. The Lancet Rheumatology. Elsevier BV. doi:10.1016/s2665-9913(20)30275-7.
Frontiers in MedicineJournal
Surfactant Protein D in Respiratory and Non-respiratory Diseases
Sorensen, Grith L.. 2018. “Surfactant Protein D in Respiratory and Non-respiratory Diseases”. Frontiers in Medicine. Frontiers Media SA. doi:10.3389/fmed.2018.00018.
clinicaltrials.govStudy
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
2021. "A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04659122.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top